Sarepta Therapeutics (SRPT) Receives Buy Rating from Oppenheimer

Oppenheimer reiterated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Wednesday. The brokerage currently has a $76.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently issued reports on SRPT. Nomura reissued a buy rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Robert W. Baird reissued an outperform rating and set a $101.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Needham & Company LLC reissued a buy rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Barclays initiated coverage on Sarepta Therapeutics in a research note on Wednesday, September 6th. They set an equal weight rating and a $46.00 target price for the company. Finally, Credit Suisse Group increased their target price on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an outperform rating in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $63.79.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $56.75 on Wednesday. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $57.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. The stock has a market capitalization of $3,670.00, a P/E ratio of -27.82 and a beta of 1.38.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 35.62% and a negative net margin of 103.87%. The business had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the prior year, the business earned ($0.95) EPS. analysts anticipate that Sarepta Therapeutics will post -3.11 earnings per share for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 38,138 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the acquisition, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 28,167 shares of company stock valued at $1,497,619 in the last ninety days. Insiders own 9.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in SRPT. Ameritas Investment Partners Inc. increased its position in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the period. Cubist Systematic Strategies LLC increased its position in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after buying an additional 2,493 shares during the period. Fox Run Management L.L.C. bought a new position in Sarepta Therapeutics during the 3rd quarter worth $204,000. Finally, Bayesian Capital Management LP bought a new position in Sarepta Therapeutics during the 2nd quarter worth $206,000. 82.02% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/28/sarepta-therapeutics-srpt-receives-buy-rating-from-oppenheimer.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

What are top analysts saying about Sarepta Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit